Bosutinib – related pleural effusion in patients with chronic myeloid leukemia

Yuzbasioglu, M. B.; Eşkazan, Ahmet Emre

doi:10.1080/14740338.2021.1867103

Cited by 5 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pericardial effusion sometimes occurred concomitantly, with 26.9% of patients taking dasatinib reported to have pleural effusion and also pericardial effusion 27. Less frequent occurrences have been observed in patients treated with bosutinib, but if used after dasatinib treatment, the proportion of pleural effusion during bosutinib treatment increases 28–30. Pleural effusions had been observed in 5–15% of patients after prolonged exposure to bosutinib 31.…”

Section: Discussionmentioning

confidence: 99%

“…27 Less frequent occurrences have been observed in patients treated with bosutinib, but if used after dasatinib treatment, the proportion of pleural effusion during bosutinib treatment increases. [28][29][30] Pleural effusions had been observed in 5-15% of patients after prolonged exposure to bosutinib. 31 Fluid retention events associated with nilotinib, such as pleural effusion, pericardial effusion and pulmonary oedema, were reported uncommon (<4% of patients) in the ENESTnd 10-year analysis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study

Huang

Cai

et al. 2023

BMJ Open

View full text Add to dashboard Cite

ObjectivesThis study aimed to conduct a thorough analysis of fluid retention-associated adverse events (AEs) associated with BCR::ABL inhibitors.DesignA retrospective pharmacovigilance study.SettingFood and Drug Administration Adverse Event Reporting System (FAERS) database for BCR::ABL inhibitors was searched from 1 January 2004 to 30 September 2021.Main outcome measuresReporting OR (ROR) and 95% CI were used to detect the signals. ROR was calculated by dividing the odds of fluid retention event reporting for the target drug by the odds of fluid retention event reporting for all other drugs. The signal was considered positive if the lower limit of 95% CI of ROR was >1. The analysis was run only considering coupled fluid retention events/BCR::ABL inhibitors with at least three cases.ResultsA total of 97 823 reports were identified in FAERS. Imatinib had the most fluid retention signals, followed by dasatinib and nilotinib, while bosutinib and ponatinib had fewer signals. Periorbital oedema (ROR=24.931, 95% CI 22.404 to 27.743), chylothorax (ROR=161.427, 95% CI 125.835 to 207.085), nipple swelling (ROR=48.796, 95% CI 26.270 to 90.636), chylothorax (ROR=35.798, 95% CI 14.791 to 86.642) and gallbladder oedema (ROR=77.996, 95% CI 38.286 to 158.893) were the strongest signals detected for imatinib, dasatinib, nilotinib, bosutinib and ponatinib, respectively. Pleural effusion, pericardial effusion and pulmonary oedema were detected for all BCR::ABL inhibitors, with dasatinib having the highest RORs for pleural effusion (ROR=37.424, 95% CI 35.715 to 39.216), pericardial effusion (ROR=14.146, 95% CI 12.649 to 15.819) and pulmonary oedema (ROR=11.217, 95% CI 10.303 to 12.213). Patients aged ≥65 years using dasatinib, imatinib, nilotinib or bosutinib had higher RORs for pleural effusion, pericardial effusion and pulmonary oedema. Patients aged ≥65 years and females using imatinib had higher RORs for periorbital oedema, generalised oedema and face oedema.ConclusionsThis pharmacovigilance study serves as a clinical reminder to physicians to be more vigilant for fluid retention-associated AEs with BCR::ABL inhibitors.

show abstract

Section: Discussionmentioning

confidence: 99%